Download
1 / 43

DiagnosisT-cell interferon-g release assays TIGRAActive TBImmunocompromised patientsHealth care workersChildrenCost-effe - PowerPoint PPT Presentation


  • 364 Views
  • Uploaded on

SINCE 1175. ERS ANNUAL CONGRESS Stockholm September 15-19, 2007 Infections year in review. TUBERCULOSIS: UPDATE ON NEW DIAGNOSTIC METHODS AND TREATMENT APPROACH. OR WHAT WE KNOW TODAY THAT WE DID NOT KNOW JUST ONE YEAR AGO. Luca Richeldi

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'DiagnosisT-cell interferon-g release assays TIGRAActive TBImmunocompromised patientsHealth care workersChildrenCost-effe' - mike_john


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide2 l.jpg

SINCE 1175

ERS ANNUAL CONGRESS

Stockholm September 15-19, 2007

Infections year in review

TUBERCULOSIS: UPDATE ON NEW DIAGNOSTIC METHODS AND TREATMENT APPROACH

OR WHAT WE KNOW TODAY THAT WE DID NOT KNOW JUST ONE YEAR AGO

Luca Richeldi

Department of Oncology, Hematology and Respiratory Disease

University of Modena and Reggio Emilia, Modena (Italy)

Potential conflicts of interest: LR participated in an advisory board meeting of Oxford Immunotec (T-SPOT.TB) and his Institution received a research grant from the Italian representative of Cellestis (QuantiFERON-TB)


Slide3 l.jpg

  • Diagnosis

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide4 l.jpg

  • Diagnosis

    • T-cell interferon-g release assays (TIGRA)

  • QuantiFERON-TB Gold (2G) (Cellestis AUS)

    CE marketed, FDA approved: CDC (US) and NICE (UK) guidelines

    • 96 wells plate

    • 2 antigens (ESAT-6 and CFP10) in 2 wells

    • single cut-off at 0.35 IU IFN-g (any antigen)

  • QuantiFERON-TB Gold In Tube (3G) (Cellestis AUS)

    CE marketed, FDA evaluation ongoing

    • 2 (or 3) tubes

    • 3 antigens (ESAT-6, CFP10 and TB 7.7) in one tube

    • single cut-off at 0.35 IU IFN-g (antigens tube)

  • T-SPOT.TB(Oxford Immunotec UK)

    CE marketed, FDA evaluation ongoing: NICE (UK) guideline

    • 96 wells plate

    • 2 antigens (ESAT-6 and CFP10) in 2 wells

    • single cut-off at 6 SFC (any antigen)


Slide5 l.jpg

TIGRA PAPERS IN PUBMED

((quantiferon* OR t-spot*) OR (elispot* AND tuberculosis) OR (elisa* AND tuberculosis))

From August to August

As of 31 August 2007


Slide6 l.jpg

I apologize with the many Authors (some of them are also good friends) of the excellent papers that I can’t mention here due to time limitations (beware of chairmen!!!)


Slide7 l.jpg

  • Diagnosis good friends) of the excellent papers that I can’t mention here due to time limitations (beware of chairmen!!!)

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide8 l.jpg

  • TST and QFT-G in: good friends) of the excellent papers that I can’t mention here due to time limitations (beware of chairmen!!!)

    • 50 healthy volunteers

    • 50 patients with active TB

    • 100 patients with NTM (ATS criteria)

Clin Infect Dis 2006


Slide9 l.jpg

NTM INFECTION good friends) of the excellent papers that I can’t mention here due to time limitations (beware of chairmen!!!)

ACTIVE TB

Clin Infect Dis 2006


Slide10 l.jpg

“We confirmed that the QFT-TB test is a useful diagnostic method for differentiating active pulmonary TB from NTM, compared with the TST.”

Clin Infect Dis 2006


Slide11 l.jpg

  • Retrospective method for study of QuantiFERON-TB Gold among 242 persons with suspected tuberculosis in San Francisco.

Clin Infect Dis 2007


Slide12 l.jpg

Clin Infect Dis 2007


Slide13 l.jpg

  • Prospective QuantiFERON-TB Gold. This sensitivity suggests that the blood assay study of 144 participants with suspected pulmonary TB (47% diagnosed with active disease) tested with QuantiFERON-TB Gold and T-SPOT.TB

Chest 2007


Slide14 l.jpg

Chest 2007


Slide15 l.jpg

J Infect 2007


Slide16 l.jpg

J Infect 2007


Slide17 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

        • more specific than TST (Kobashi)

        • not to be used alone to diagnose TB (Dewan)

        • have high negative predictive value (Kang)

        • longitudinal assessment might be useful (Dheda)


Slide18 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide19 l.jpg

  • Prospective late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising study of QuantiFERON-TB Gold In Tube and TST among 294 HIV-infected subjects at risk for TB infection in San Francisco.

Am J Respir Crit Care Med 2007


Slide20 l.jpg

  • Subjects with a CD4 late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising count of less than 100 cells/mm3 had a RR of an indeterminate result of 4.24 (95% CI 1.55-11.61; p0.003) compared with those with a CD4 count of 100 or more.

  • Overall concordance between QFT and TST was high, but agreement among subjects with positive tests by either modality was low.

Am J Respir Crit Care Med 2007


Slide21 l.jpg

  • Prospective late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising study of T-SPOT.TB and TST (N=70) among 201 HIV-infected subjects at risk for TB infection and disease in London.

Clin Exp Immunol 2007


Slide22 l.jpg

  • 2.0% indeterminate T-SPOT.TB results: late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising correlation (p=0.017) between CD4 counts and PHA response.

  • Sensitivity for active TB not affected by CD4 counts.

Clin Exp Immunol 2007


Slide23 l.jpg

  • Prospective late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising study of T-SPOT.TB, QuantiFERON-TB Gold and TST among 160 individuals screened for HIV-infection (74 HIV+) in a TB endemic South Africa area.

Am J Respir Crit Care Med 2007


Slide24 l.jpg

Am J Respir Crit Care Med 2007


Slide25 l.jpg

  • TST is negatively influenced by CD4 counts. late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

  • T-SPOT.TB tends to have more positive results in the lower CD4 group.

Am J Respir Crit Care Med 2007


Slide26 l.jpg

More on the meaning of k values in TIGRA studies in the MtP session on LTBI at 1 pm today (room K24)

Am J Respir Crit Care Med 2007


Slide27 l.jpg

  • Prospective late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising study of T-SPOT.TB and TST among 203 patients with end stage renal disease in Toronto, Canada. Expert physician panel also evaluated patients for LTBI diagnosis.

Clin J Am Soc Nephrol 2007


Slide28 l.jpg

  • T-SPOT.TB scored late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising more positive results, in agreement with the expert physician panel. TST probably highly insensitive in this high-risk group.

Clin J Am Soc Nephrol 2007


Slide29 l.jpg

  • Prospective late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising study of T-SPOT.TB and TST among 197 hematological patients and 324 TB contacts in Milan, Italy.

New Microbiol 2007


Slide30 l.jpg

  • T-SPOT.TB (36%) scored late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising significantly more positive results than TST (17%) among hematological patients; on the contrary, TST was more positive among TB contacts (60% were BCG vaccinated).

New Microbiol 2007


Slide31 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

        • Indeterminate QFT-IT in low CD4 HIV (Luetkemeyer)

        • Low QFT-IT vs TST agreement in HIV (Luetkemeyer)

        • Few indeterminate T-SPOT.TB results in HIV (Clark)

        • Low CD4 and positive T-SPOT.TB: active TB (Clark)

        • TIGRA unaffected by HIV infection (Rangaka)

        • Low agreement between TIGRA and TST (Rangaka)

        • TST highly insensitive in ESRD patients (Passalent)

        • TST insensitive in hematological patients (Piana)


A look into the future l.jpg

The next F1 world champion late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

A LOOK INTO THE FUTURE …


A look into the future of tigra l.jpg

J Immunol late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising 2007

CD4 IFN-g

CD4 IFN-g / IL-2

CD4 IL-2

A LOOK INTO THE FUTURE OF TIGRA

  • Distinct T cell functional signatures suggest a novel immune marker of clinical status in TB infection: dual-cytokine TIGRA?


Slide34 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide35 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

        • QFT-G IT useful in Russian HCWs (Drobniewsky)

        • QFT-G IT and TST disagree in German HCWs (Nienhaus)

        • Very few QFT-G-positive Danish HCWs (Soborg)

      • Children

        • TIGRA more specific than TST in children (Detjen)

        • Retrospective QFT-G in children: NICE GL issue (Taylor)

      • Cost-effectiveness

        • TST and QFT-G are cost-effective in contacts (Diel)

        • TST and T-SPOT.TB are cost-effective in contacts (Diel)


Slide36 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide37 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

      • NAATS useful in excluding AFB+ TB (Greco)

    • Serologic tests

      • No role at the moment (Steingart x 2)

    • High prevalence areas

      • Sputum submission instructions effective(Khan)

      • LAMP robust, easy and promising (Boehme)


Slide38 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide39 l.jpg

Proteins late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising 2007

  • Biomarkers

    • IL-23, FoxP3 promising markers(Fletcher)

    • Change in mycobacterial burden (Perrin)

  • New drugs

    • Little data available on rifabutin in HIV(Davies)

    • TMC 207 (diarylquinoline) most promising drug

  • Therapy


Tb clinical development pipeline l.jpg
TB CLINICAL DEVELOPMENT PIPELINE late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

*Institut de Recherche pour le Developement

World Health Organization, Tropical Disease Research

Centers for Disease Control and Prevention

Novel compounds, highlighted in blue italics, are active against MDR/XDR TB

Courtesy Mario Raviglione, WHO


Slide41 l.jpg

2015 late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

Science 2006


Slide42 l.jpg

  • Diagnosis late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

    • T-cell interferon-g release assays (TIGRA)

      • Active TB

      • Immunocompromised patients

      • Health care workers

      • Children

      • Cost-effectiveness

    • Nucleic acid amplification assays (NAAT)

    • Serologic tests

    • High prevalence areas

  • Therapy

    • Biomarkers

    • New drugs


Slide43 l.jpg

SINCE 1175 late phase of treatment had positive TIGRA (83% vs 19% p<0.01). In a low burden setting TIGRA may be a promising

ERS ANNUAL CONGRESS

Stockholm September 15-19, 2007

Infections year in review

TUBERCULOSIS: UPDATE ON NEW DIAGNOSTIC METHODS AND TREATMENT APPROACH

Luca Richeldi

Department of Oncology, Hematology and Respiratory Disease

University of Modena and Reggio Emilia, Modena (Italy)


ad